Drug Trial Radar · NCT03590366
A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea
Last checked: Nov 19, 2026Latest source record: Sep 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Jul 2, 2018
Primary completion
Feb 11, 2019
Study completion Mar 5, 2019
Sponsor
- Lead sponsor
- AOBiome LLCIndustry
- Sponsor type
- Industry
- Collaborators
- bioRASI, LLC
- First posted
- Jul 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.
Conditions
- Rosacea
Interventions
B244Biological
B244 Suspension
VehicleBiological
Vehicle suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0Time frame: Baseline to Day 84
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Tampa Bay Medical Research
Clearwater, Florida
Veritas Research Corp
Miami, Florida
South Coast Research Center, Inc.
Miami, Florida
FXM Research Corp.
Miami, Florida
FXM Research Miramar
Miramar, Florida
Wake Research Associates, LLC
Raleigh, North Carolina
Paddington Testing Co.
Philadelphia, Pennsylvania
Omega Medical Research
Warwick, Rhode Island
West Houston Clinical Research Service
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.